Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salmeterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 18/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 17/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | FPR3 | P25089 | 1/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | HTR1D | P28221 | 1/20 | 1.00 |
| ▸ | HTR1B | P28222 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salmeterol SCHEMBL29393289 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL4767 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL4768 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL29397921 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| SCHEMBL4450046 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL7176067 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL28889602 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL29266779 | 0.99 | ADRB2 (0.98) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| Salmeterol SCHEMBL6152211 | 0.98 | ADRB2 (0.96) | ADRB2ADRB1ADRB3KDM4EMEN1 | |
| SCHEMBL4454918 | 0.98 | ADRB2 (0.96) | ADRB2ADRB1ADRB3KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2849738-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | Techfields Pharma Co., Ltd. (CN) | 2015-03-25 | — | — | EP | claimed |
| WO-2013170655-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2013-11-21 | — | — | WO | claimed |
| US-20240033232-A1 | New use of (R)-B2-agonists in treatment of sepsis and acute respiratory distress syndrome | TAN WEN (CN) | 2024-02-01 | — | — | US | disclosed |
| US-20220362174-A1 | Use of R-enantiomer Beta2-agonists for prevent and treatment of pulmonary inflammation and inflammatory remodeling for reduced adverse effects | TAN WEN (CN) | 2022-11-17 | — | — | US | disclosed |
| WO-2022191828-A1 | NEW USE OF (R)-β2-AGONISTS IN TREATMENT OF SEPSIS AND ACUTE RESPIRATORY DISTRESS SYNDROME | TAN WEN (CN) | 2022-09-15 | — | — | WO | disclosed |
| EP-2849738-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | Techfields Pharma Co., Ltd. (CN) | 2015-03-25 | — | — | EP | disclosed |
| US-8710036-B2 | Carbonate and carbamate modified forms of glucocorticoids in combination with β2 adrenergic agonists | SUNOVION PHARMACEUTICALS INC. (US) | 2014-04-29 | — | — | US | disclosed |
| WO-2013170655-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2013-11-21 | — | — | WO | disclosed |
| US-20130244988-A1 | CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH B2 ADRENERGIC AGONISTS | SUNOVION PHARMACEUTICALS INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8445470-B2 | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists | SUNOVION PHARMACEUTICALS INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20090163456-A1 | CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH B2 ADRENERGIC AGONISTS | SEPRACOR INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-7253156-B2 | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists | SEPRACOR INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20060148775-A1 | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists | SEPRACOR INC. (US) | 2006-07-06 | — | — | US | disclosed |
| US-20060094701-A1 | Use of beta-2 bronchodilator drugs | MORLEY JOHN | 2006-05-04 | — | — | US | disclosed |
| EP-1635844-A1 | SALMETEROL AND CICLESONIDE COMBINATION | ALTANA Pharma AG (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050009798-A1 | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists | SEPRACOR INC. (US) | 2005-01-13 | — | — | US | disclosed |
| WO-2004103379-A1 | SALMETEROL AND CICLESONIDE COMBINATION | ALTANA PHARMA AG (DE) | 2004-12-02 | — | — | WO | disclosed |
| US-20040192783-A1 | Use of B-2 bronchodilator drugs | MORLEY JOHN (CH) | 2004-09-30 | — | — | US | disclosed |
| US-20020132830-A1 | Use of beta 2 bronchodilator drugs | SEPRACOR INC. (US) | 2002-09-19 | — | — | US | disclosed |
| EP-0422889-A2 | Phenethanolamine compounds | GLAXO GROUP LIMITED (GB) | 1991-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148775-A1 | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists | ADRB2, ADRA2C, NR3C2 | ADRB2 1/4885ADRB1 7/4885ADRB3 11/4885 |
| US-20130244988-A1 | CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH B2 ADRENERGIC AGONISTS | ADRB2, CHRM2, NR3C2 | ADRB2 1/4885ADRB1 8/4885ADRB3 13/4885 |
| US-20090163456-A1 | CARBONATE AND CARBAMATE MODIFIED FORMS OF GLUCOCORTICOIDS IN COMBINATION WITH B2 ADRENERGIC AGONISTS | ADRB2, CHRM2, NR3C2 | ADRB2 1/4885ADRB1 8/4885ADRB3 13/4885 |
| US-20050009798-A1 | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists | ADRB2, ADRA2C, NR3C2 | ADRB2 1/4885ADRB1 7/4885ADRB3 11/4885 |
| US-20040192783-A1 | Use of B-2 bronchodilator drugs | ADRB2, ADRA2B, BDKRB2 | ADRB2 1/4885ADRB1 7/4885ADRB3 9/4885 |
| US-20020132830-A1 | Use of beta 2 bronchodilator drugs | ADRB2, ADRA2B, ADRB1 | ADRB2 1/4885ADRB1 3/4885ADRB3 6/4885 |
| US-20060094701-A1 | Use of beta-2 bronchodilator drugs | ADRB2, ADRA2B, ADRB1 | ADRB2 1/4885ADRB1 3/4885ADRB3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.